BME$GRFS
Grifols SA · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
GRFS Q2 2024 — €3.44B revenue, 0.05 EPS
Fibrinogen clinical trial in H1’24 Solid business and product fundamentals High - growth industry with compelling market dynamics On track with FY24 guidance backed by strong first half results 05 06 . Grifols SA reported Q2 2024 results. Diluted EPS came in at 0.05. Net income of €36.3M. Headline numbers extracted from the Form 6-K press release; narrative is light because this row was processed without an LLM call.
- Revenue: €3.44B.
- Diluted EPS: 0.05.
- Net income: €36.3M.
Headline financials
Revenue & EPS history
Grifols · Revenue · Quarterly
$1.95B
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+38.2%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-0.2%
Avg return
30 days after
22%
12 / 55 earnings
Positive
+1950.4%
Q4 2010
Best reaction
-8.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | +3.5% | +11.6% | +22.8% | |
| Q1 2024 | +0.7% | +1.4% | +10.5% | |
| Q4 2024 | -3.8% | -2.3% | +17.7% | |
| Q3 2023 | +0.0% | -5.6% | -14.0% | |
| Q2 2023 | +2.7% | +1.5% | +17.1% | |
| Q4 2022 | +0.0% | -0.5% | +14.1% | |
| Q1 2023 | +0.0% | -4.4% | -0.1% | |
| Q3 2022 | +0.0% | +10.3% | +5.5% | |
| Q2 2022 | -7.5% | -21.8% | -24.9% | |
| Q1 2022 | -0.0% | +0.3% | -9.1% | |
| Q3 2021 | -5.1% | -0.1% | -12.1% | |
| Q2 2021 | +4.6% | -0.6% | -6.5% | |
| Q1 2021 | -0.2% | +5.8% | -2.7% | |
| Q4 2020 | +0.0% | -5.3% | +3.9% | |
| Q3 2020 | +0.0% | +8.1% | +7.1% | |
| Q2 2020 | +0.0% | -1.6% | -17.2% | |
| Q1 2020 | +0.4% | -3.6% | -1.0% | |
| Q4 2019 | -8.9% | -7.5% | -15.4% | |
| Q3 2019 | +0.0% | +4.5% | +7.0% | |
| Q2 2019 | +0.0% | -3.7% | -5.6% | |
| Q1 2019 | +0.0% | -4.0% | -2.5% | |
| Q4 2018 | -4.4% | +0.8% | +3.0% | |
| Q3 2018 | +0.0% | +0.0% | -8.7% | |
| Q2 2018 | +0.0% | -1.2% | -1.1% | |
| Q1 2018 | +0.0% | +6.6% | +8.1% | |
| Q4 2017 | +0.0% | -5.0% | -5.2% | |
| Q3 2017 | +8.0% | +0.3% | -4.3% | |
| Q2 2017 | +0.0% | +3.6% | +2.1% | |
| Q1 2017 | +0.0% | -2.1% | -1.0% | |
| Q4 2016 | +8.2% | +3.0% | +8.9% | |
| Q3 2016 | +0.0% | -0.8% | -8.3% | |
| Q2 2016 | +0.0% | +4.1% | +6.6% | |
| Q4 2015 | +0.0% | — | — | |
| Q1 2016 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q4 2014 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | -2.7% | — | — | |
| Q4 2013 | +0.7% | — | — | |
| Q1 2014 | -0.1% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q3 2012 | +152.0% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2010 | +1950.4% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q3 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro